Suwannaying K.Monsereenusorn C.Rujkijyanont P.Techavichit P.Phuakpet K.Pongphitcha P.Chainansamit S.o.Chotsampancharoen T.Winaichatsak A.Traivaree C.Sathitsamitphong L.Kanjanapongkul S.Komvilaisak P.Sanpakit K.Photia A.Seksarn P.Wiangnon S.Hongeng S.Mahidol University2023-06-182023-06-182022-09-01Pediatric Blood and Cancer Vol.69 No.9 (2022)15455009https://repository.li.mahidol.ac.th/handle/20.500.14594/85601Background: Neuroblastoma is the most common extracranial malignant solid tumor during childhood. Despite intensified treatment, patients with high-risk neuroblastoma (HR-NBL) still carry a dismal prognosis. The Thai Pediatric Oncology Group (ThaiPOG) proposed the use of a multimodality treatment to improve outcomes of HR-NBL in non-immunotherapy settings. Methods: Patients with HR-NBL undergoing ThaiPOG protocols (ThaiPOG-NB-13HR or -18HR) between 2013 and 2019 were retrospectively reviewed. Patient demographic data, treatment modalities, outcomes, and prognostic factors were evaluated and analyzed. Results: A total of 183 patients with HR-NBL undergoing a topotecan containing induction regimen were enrolled in this study. During the consolidation phase (n = 169), 116 patients (68.6%) received conventional chemotherapy, while 53 patients (31.4%) underwent hematopoietic stem cell transplantation (HSCT). The 5-year overall survival (OS) and event-free survival (EFS) were 41.2% and 22.8%, respectively. Patients who underwent HSCT had more superior 5-year EFS (36%) than those who received chemotherapy (17.1%) (p =.041), although they both performed similarly in 5-year OS (48.7% vs. 39.8%, p =.17). The variation of survival outcomes was observed depending on the number of treatment modalities. HSCT combined with metaiodobenzylguanidine (MIBG) treatment and maintenance with 13-cis-retinoic acid (cis-RA) demonstrated a desirable 5-year OS and EFS of 65.6% and 58.3%, respectively. Poorly or undifferentiated tumor histology and cis-RA administration were independent factors associated with relapse and survival outcomes, respectively (p <.05). Conclusion: A combination of HSCT and cis-RA successfully improved the outcomes of patients with HR-NBL in immunotherapy inaccessible settings.MedicineArticleSCOPUS10.1002/pbc.297572-s2.0-851338660171545501735560972